Compare PLBY & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLBY | BNR |
|---|---|---|
| Founded | 1953 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.4M | 179.7M |
| IPO Year | 2020 | 2019 |
| Metric | PLBY | BNR |
|---|---|---|
| Price | $1.30 | $9.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 14.5K |
| Earning Date | 05-11-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,928,000.00 | N/A |
| Revenue This Year | $9.17 | $111.65 |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $1.19 | $2.95 |
| 52 Week High | $2.75 | $41.72 |
| Indicator | PLBY | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 26.83 |
| Support Level | $1.22 | $7.99 |
| Resistance Level | $1.94 | $9.70 |
| Average True Range (ATR) | 0.08 | 1.19 |
| MACD | 0.01 | -0.50 |
| Stochastic Oscillator | 33.90 | 6.87 |
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.